Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer-Reference-Cited by-同舟云学术

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Rosser Charles J.¹^ORCID,Tikhonenkov Sergei¹,Nix Jeffrey W.²,Chan Owen T.M.¹,Ianculescu Irina³,Reddy Sandeep³⁴,Soon-Shiong Patrick⁴

Affiliation:

1. Clinical & Translational Research Program, University of Hawaii Cancer Center,Honolulu, Hawaii

2. Department of Urology, University of Alabama, Birmingham, Alabama

3. ImmunityBio, Inc., Culver City, California

4. NantHealth Inc, Culver City, California

Funder

NantHealth Inc

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1912885

Reference23 articles.

1. Cancer Statistics, 2021

2. Epidemiology of Bladder Cancer

3. null

4. Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

5. THE NATURAL HISTORY OF BLADDER CANCER

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer;annals of urologic oncology;2024-08-29

2. Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?;Journal of Clinical Medicine;2024-07-14

3. Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2024-07-02

4. Nogapendekin alfa Inbakicept: First Approval;Drugs;2024-07

5. Immunotherapy in the Treatment of Cancer: Today and Tomorrow;Current Molecular Biology Reports;2024-05-20